Novacyt Stock

Novacyt FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Novacyt (ALNOV.PA) as of Sep 3, 2026 is 27.98 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 92.31 % — a change of -69.69% (lower).

FCF Conversion

27.98 %

YoY

-69.69%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Novacyt is 2026 27.98 % . FCF Conversion Rate (FCF/EBITDA) of Novacyt was 2025 92.31 % . It decreases by -69.69% lower compared to the previous year.

The Novacyt FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2017
103.35 GBP
Jan 1, 2018
40.76 GBP
Jan 1, 2019
19.92 GBP
Jan 1, 2020
76.87 GBP
Jan 1, 2021
-119.13 GBP
Jan 1, 2022
54.97 GBP
Jan 1, 2023
92.31 GBP
Jan 1, 2024
27.98 GBP
The Novacyt FCF Conversion history
YEARFCF ConversionYoY
27.98 %-69.69%
92.31 %+67.92%
54.97 %-146.15%
-119.13 %-254.97%
76.87 %+285.97%
19.92 %-51.13%
40.76 %-60.56%
103.35 %+89.90%
54.42 %+22.57%
44.40 %-34.38%
67.66 %
Access this data via the Eulerpool API

Novacyt Stock analysis

What does Novacyt do? Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. The company was founded in 2006 and has experienced impressive growth since then. Its headquarters are located in Paris. Novacyt's business model revolves around the development and marketing of diagnostic products and technologies, particularly molecular diagnostic kits and reagents used for identification and quantification of microorganisms, viruses, and genetic differences. These products are commonly used in medical research, clinical diagnostics, and environmental analysis. Novacyt is divided into several divisions, each offering different products and services. Its diagnostic business specializes in the research, development, and marketing of molecular diagnostic kits, including the Primerdesign Kits specifically designed for COVID-19 identification. The company also provides laboratory and service offerings, such as DNA sequencing, qPCR analysis, sample preparation, and PCR disinfection. Additionally, Novacyt offers various diagnostic tests capable of detecting genetic differences and mutations. Its PathFlow division focuses on improving the process from diagnosis to therapy and follow-up, particularly for oncology patients. In response to the COVID-19 pandemic, Novacyt quickly launched a PCR test kit for COVID-19, which has been approved in numerous countries worldwide. Novacyt has successfully established itself as a key player in the fight against the pandemic. In summary, Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. Through its divisions, the company ensures the optimal utilization of molecular diagnostic tests. Novacyt has become an important player in the fight against the pandemic through its rapid response and development of molecular diagnostic kits for COVID-19, establishing itself as a reliable and innovative partner for medical research and clinical diagnostics. Novacyt is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Novacyt stock

FCF Conversion Rate (FCF/EBITDA) of Novacyt is 27.98 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of Novacyt changed from 92.31 % to 27.98 %, representing a -69.69% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Novacyt since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Novacyt with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

Cash Flow — Novacyt

All Key Metrics — Novacyt